An Introduction to Anti-VEGF Therapy
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of several retinal conditions that once led to significant and irreversible vision loss. Prior to its introduction, diseases such as neovascular age-related macular degeneration (nAMD) frequently resulted in rapid, irreversible central vision decline. The advent of intravitreal anti-VEGF injections now allows most patients to maintain vision, and many experience meaningful improvement. This article aims to provide a foundational understanding of the therapeutic mechanism, primary clinical indications, current treatment paradigms, and the future trajectory of anti-VEGF agents, highlighting developments focused on maximizing efficacy and reducing patient burden.
